Zenas BioPharma, Inc. cotiza a 26.40 USD y tiene una capitalización bursátil de $1.7B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various i…
| Periodo | 2026-08 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-1.77 | $-1.46 | $-1.39 |
| Estimado | $-0.75 | $-0.75 | $-1.54 | $-1.19 |
| Sorpresa | — | -136.0% | +5.2% | -16.8% |
| Métrica | ZBIO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -3830.6% | -38.6% | -3792.0% |
| Net Margin | -3777.4% | -33.6% | -3743.8% |
| FCF Margin | -1723.5% | -13.9% | -1709.7% |
| ROE | -156.0% | -40.4% | -115.6% |
| ROA | -98.5% | -32.0% | -66.4% |
| Current Ratio | 5.61 | 2.84 | +2.77 |
| Debt / Equity | 0.32 | 0.28 | +0.04 |